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Effect of surface hydrophobicity of therapeutic protein loaded 
in polyelectrolyte nanoparticles on transepithelial permeability
Oral delivery of protein drugs is greatly limited by low hydro-
phobicity, an important determinant for intestinal epithe-
lial permeation and bioavailability. Herein, surface proper-
ties of recombinant erythropoietin were investigated using 
the fluorescent dye bis-ANS to monitor relative hydropho-
bicity for correlation with permeabilities with Caco-2 cells. 
At various pHs, bis-ANS fluorescence intensity indicated 
different surface hydrophobicities of erythropoietin mole-
cules. Erythropoietin incorporated in chitosan or chitosan-
trimethylchitosan (CS-TMC) nanoparticles prepared by 
polyelectrolyte complexation and ionotropic gelation with 
tripolyphosphate also showed different surface hydropho-
bicities. Chitosan nanoparticles with erythropoietin pro-
vided the most hydrophobic surface, followed by free 
erythropoietin (in water) and that loaded into CS-TMC 
nanoparticles. Chitosan nanoparticles were more effective 
than CS-TMC nanoparticles for permeation of erythropoi-
etin across Caco-2 cell monolayers; the lowest permeability 
was shown by erythropoietin itself. Thus, hydrophilic pro-
tein molecules complexed with polyelectrolytes can pro-
vide more hydrophobic surfaces that enhance transepithe-
lial permeability. This bis-ANS method also provides 
valuable information for the design of polyelectrolyte 
nanoparticules for oral delivery of protein drugs.
Keywords: erythropoietin, bis-ANS fluorescence intensity, 
chitosan, Caco-2 model, membrane permeability, oral drug 
delivery
Recent advances in DNA recombinant technology have allowed the production of 
therapeutic proteins on an industrial scale. These have advantages over conventional 
small-molecule drugs since they can provide more specific, effective and safer treatments. 
Hence, therapeutic proteins represent the future of mainstream drugs (1, 2).
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The majority of currently marketed peptide and protein drugs are administered via 
injection although such administration is less acceptable to the patient due to pain and 
discomfort that can frequently lead to low patient compliance. However, although a highly 
attractive approach, oral delivery of proteins remains a significant challenge in the design 
of drug delivery systems because of their unfavourable physicochemical properties. Major 
limitations for effective oral protein drug bioavailability (which can frequently be < 1 %) 
include their relatively high molecular mass, hydrophilic nature, instability due to varia-
tions in pH and enzymes in the gastrointestinal tract (including the natural microbiota), 
and their poor mucosal and epithelial permeability (3–6). Indeed, as the benefits of thera-
peutic proteins continue to increase, there will be a growing need for improved oral drug 
delivery systems.
Nanoparticles (NPs) composed of polymers or lipids have emerged as a major driver 
among delivery systems for oral administration of protein drugs (7–9). In particular, en-
capsulation of a protein into such carriers can protect protein drugs from acidic and enzy-
matic degradation, control their release, and enhance their absorption in the small intes-
tine (7). Integrity of an encapsulated protein has a crucial impact on its pharmacological 
efficiency. Many and varied approaches to improving encapsulation and drug stability 
have been investigated (8–10). The parameters of NPs that favour permeation through the 
barriers in the gut include small particle size, colloidal stability, and suitable hydrophilic/
hydrophobic surface properties (8). It is generally agreed that absorption increases with a 
decreasing particle diameter. Studies on polystyrene latex particles of 50 nm to 3 µm in 
diameter have revealed that maximum absorption occurs with particles of 50 to 100 nm, 
while particles > 1 µm are trapped in the lymphoid follicles of the ileum (11).
NPs with a more hydrophobic surface can cross the epithelial barrier more efficiently 
than those with a hydrophilic surface, although hydrophobic NPs are less stable and show 
lower mucopermeability (12). To ensure both features, a suitable hydrophilic/hydrophobic 
balance needs to be provided (3, 8, 13, 14). From the perspective of nanoparticle-membrane 
interactions, many studies have demonstrated different effects of hydrophobic NPs on the 
lipid bilayers (14). These studies have defined the key factor for improved permeability as 
the shift in the hydrophilic to more hydrophobic character of protein drugs. Thus, the 
hydrophobic character of NPs regulates their entry into epithelial cells and their transition 
across and exit from these cells on the basolateral side, and hence their entry into the sys-
temic circulation (13, 15, 16).
Characterization of the surface hydrophobicity of free protein molecules or proteins 
incorporated in NPs is thus particularly relevant in the design of drug delivery systems. 
Hydrophobicity of a protein surface depends not only on the chemistry of the underlying 
amino acids and functional groups of matrix polymers, but also on the precise chemical 
pattern and topographical context presented by the surface. Characterization of such con-
text-dependent hydrophobicity at nanoscale resolution is not a trivial task (17). In general, 
the hydrophobicity of composed particles has been determined by indirect methods (e.g., 
partition coefficients or log P, thin layer chromatography, various computational methods) 
(3, 13). These measurements constitute a limitation for rapid evaluation of protein drug 
molecules in their native form. For in-depth analysis, fluorescent dyes offer an analytical 
alternative for determination of hydrophobicity in terms of pharmaceutical formulations. 
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Such dyes include 1-anilinonaphtalene-8-sulfonate (ANS), 4,4’-bis-ANS (bis-ANS), Nile 
red, thioflavin T, dye 9-(dicyanovinyl)-julolidine and Congo red, which can interact non-
covalently with protein surfaces. In this context, ANS and its dimeric analogue bis-ANS 
have been amongst the most frequently used dyes for protein characterization (18). Fluo-
rescence of these dyes is sensitive to their environment, with respect to polarity, viscosity 
and temperature. Although all of these dyes interact hydrophobically or electrostatically 
with solutes (e.g., proteins), it has been shown for bis-ANS that hydrophobic interactions 
dominate over electrostatic interactions (18, 19). Thus, in the development of composed 
NPs, these dyes can provide a way of easily determining surface hydrophobicity. In addi-
tion, it is important to investigate the effect of protein or nanoparticle polarity on Caco-2 
cell monolayers, since they closely mimic the biological properties of the intestinal epithe-
lial cells (20–22). Permeation of free protein drugs and those loaded into NPs in terms of 
their surface hydrophobicity has not been studied yet.
Recombinant human erythropoietin (EPO) was selected as the model protein drug. It 
is a glycoprotein hormone, which is the principal regulator of red blood cell formation (23). 
Due to the required high doses of parenterally administered EPO, severe side effects have 
been reported for cancer patients taking EPO and receiving chemotherapy and/or radia-
tion therapy (24). Therefore, there is an unmet need to develop new and improved EPO 
delivery systems for its oral administration, which might then allow low-dose long-term 
therapy.
In the present study, surface properties of EPO molecules in solution and those incor-
porated into NPs were investigated using the fluorescent dye bis-ANS to determine its 
relative surface hydrophobicity influencing the delivery of EPO across the intestinal epi-
thelial barrier. The hypothesis was that the nanoparticle formation by complexation of 
charged EPO molecules with oppositely charged polyelectrolyte, i.e., chitosan (CS) and/or 
trimethylchitosan (TMC), has a decisive consequence on the surface hydrophobicity and 
on permeability through the Caco-2 cells. The study could provide a protocol that can be 
used to determine the hydrophobicity and predict the permeability of new protein drugs 
and to design nanoparticulate delivery systems for their oral administration.
EXPERIMENTAL
Materials
Recombinant human erythropoietin (herein EPO) was kindly donated by Sandoz Bio-
pharmaceuticals Mengeš, Slovenia. Low molecular weight chitosan (50–190 kDa; deacety-
lation degree 75–85 %; viscosity 20–200 mPa s in 1 % (m/V) acetic acid solution) and sodium 
tripolyphosphate (TPP) were from Sigma-Aldrich, USA. N- TMC with 47 % quaternization 
and not O-methylated was synthesized and characterized using 1H NMR. The extrinsic 
fluorescence dye bis-ANS was from Molecular Probes, USA. Low molecular mass marker 
fluorescein was from Sigma Aldrich, USA. The Caco-2 cell line was from the American 
Tissue Culture Collection, USA. Dulbecco’s modified eagle’s medium (DMEM), trypsin, 
heat-inactivated foetal bovine serum, L-glutamine, non-essential amino acids, and bovine 
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serum albumin were from Sigma-Aldrich, USA. Antibiotic/antimycotic solutions and 
phosphate-buffered saline (PBS) were from Invitrogen, USA.
Permeability experiments were performed in 12-well plates (Transwell, Costar 3460; 
Costar, UK) on polyester permeable supports (membrane growth area 1.12 cm2; pore size 
0.4 µm; Costar, UK). Antibodies and reagents for ELISA were from R&D Systems (Min-
neapolis, USA). All other chemicals used were of analytical grade.
Preparation of erythropoietin-loaded nanoparticles
NPs were prepared under mild conditions using the polyelectrolyte complexation and 
ionotropic gelation method (5, 10, 25). For the EPO-loaded NPs, a solution of EPO (2.67 mg 
mL–1) was initially prepared in phosphate buffer (50.0 mmol L–1 NaHPO4, 150.0 mmol L
–1 
NaCl, adjusted with 0.5 mol L–1 NaOH to pH 7.4), of which 0.225 mL was added dropwise 
to 2 mL of CS or a mixture of CS and TMC (CS-TMC ratio 1:1) solution (2 mg mL–1 in 0.25 
% (V/V) aqueous acetic acid, pH 4.6), at 25 °C for 30 min, under magnetic stirring (300 rpm). 
Then 0.900 mL of TPP solution (1 mg mL–1 in water) was added dropwise into the disper-
sion and stirred for 45 min to obtain the final colloidal dispersion of CS/EPO/TPP and 
CS-TMC/EPO/TPP NPs. These were thus composed of a polymer or a mixture of polymers 
(CS and/or TMC) 1.28 mg mL–1, EPO 0.192 mg mL–1 and TPP 0.288 mg mL–1. In the same 
way, empty NPs were prepared, where EPO was replaced by phosphate buffer (pH 7.4). The 
obtained dispersion of the NPs showed the characteristic Tyndall effect.
Characterization of nanoparticles
The NPs were characterized according to their hydrodynamic size, polydispersity 
index and surface zeta potential using Zetasiser Nano ZS; Malvern Instruments, UK. 
These measurements were carried out at least in triplicate, at 25 °C, using a He-Ne laser 
(λ = 633 nm) with back-scatter detection (scattering angle, 173°). Data were collected using 
the Zetasizer software (version 6.20) as the hydrodynamic size (using the Stokes-Einstein 
equation), polydispersity index, and zeta potential (using the Smoluchowski approxima-
tion for the Henry equation). Laser light scattering measurements were used to investigate 
whether aggregation occurred and to follow dispersion instability.
A scanning electron microscope (SEM, JSM-7001F; Jeol, Japan) was used to evaluate 
the nanoparticle morphology, with an acceleration voltage of 1.5 kV and a secondary elec-
tron detector. Scanning electron microscopy images were taken of the freshly prepared 
NPs after they were dried in a vacuum dryer (Termo Scientific 36185; Fischer Scientific, 
USA), at 25 °C for 24 h, with the samples deposited on double-sided carbon tape (diameter, 
12 mm; Oxford Instruments, UK).
Determination of loading capacity of erythropoietin in nanoparticles
The amount of EPO associated with the NPs represents the loading capacity (LC). This 
is the difference between the total EPO initially used to prepare the NPs and the amount 
of non-associated EPO after nanoparticle separation, expressed as a percentage of the total 
nanoparticle mass, as defined in Eq. (1):
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  ( ) ( )
total amount of EPO-free EPO in supernatant
 % =  × 100
mass of nanoparticles
LC   (1).
The free EPO content in the supernatant was determined after ultracentrifugation of 
1.5 mL of nanoparticle dispersion at 128,307 × g for 20 min, using reverse-phase HPLC 
(Waters HPLC system; Waters Corporation, USA) with a C18 column (YMC-Pack ODS-AQ; 
150 × 4.6 mm; 3 µm). Mobile phase A was 10 % acetonitrile in 0.1 % aqueous trifluoroacetic 
acid, and mobile phase B was 90 % acetonitrile in 0.1 % aqueous trifluoroacetic acid. Gradi-
ent elution (flow rate 1 mL min–1; 35 °C) went from 35 to 65 % (V/V) buffer B in buffer A, 
providing five column volumes over 30 min of elution. Detection was at 215 and 280 nm.
Determination of surface hydrophobicity using fluorescent dye
The bis-ANS dye was used for characterization of the surface hydrophobicity of EPO, 
either alone (free in solution) or loaded in NPs. Fluorescence emission spectra of bis-ANS 
in different media were recorded to evaluate the impact of medium polarity and pH on 
surface hydrophobicity. The stock solution of EPO (2.67 mg mL–1) was added into water, 
phosphate buffer pH 7.4 and 0.25 % (V/V) acetic acid, and into media with NPs to achieve 
the same final concentration of 0.19 mg mL–1 EPO as in NPs. To evaluate surface character-
istics of the EPO-loaded NPs, the fluorescence emission spectra were recorded for EPO in 
solution and loaded into NPs (CS/EPO/TPP; CS-TMC/EPO/TPP), all with the same medium 
composition and at the same pH. Into 180 µL of these samples, 20 µL 50 µmol L–1 bis-ANS 
was added to achieve the final concentration of bis-ANS 5 µmol L–1. Fluorescent intensity 
of bis-ANS in different samples was measured using a UV-VIS spectrofluorimeter (Safire2, 
Tecan Austria GmbH, Austria). The excitation wavelength was 385 nm and emission scans 
were recorded from 420 to 650 nm, with slits of 1 nm. The Z-position was set to 11,700 µm, 
and a gain of 65 was used. Under these conditions, the inner filter effect was negligible.
Determination of EPO permeability in the Caco-2 cell monolayer
For transport experiments, Caco-2 cells were seeded and cultured in 12-well perme-
able support plates at a seeding density of 1 × 105 cells/well in a volume of 0.5 mL DMEM 
supplemented with 10 % (V/V) foetal bovine serum, 1 % (V/V) L-glutamine, 1 % (V/V) non-
essential amino acids and 1 % (V/V) antibiotics/antimycotics. The cells were grown in an 
atmosphere containing 5 % CO2 at 37 °C for 21 days, with the medium changed every 2 to 
3 days. One hour before the experiment, the growth medium was changed to permeation 
medium: Hank’s balanced salt solution, buffered with 30 mmol L–1 N-(2-hydroxyethyl) 
piperazine-N-(2-ethanosulfonic acid) (HEPES) at pH 5.6, and the cells were left to equili-
brate.
Transepithelial electrical resistance of the Caco-2 cell monolayer and permeability 
experiments were performed after 3 weeks of Caco-2 cell culturing (cell passages 48–58) 
on a permeable support in Transwell plates. Tightness of the cell monolayer was tested by 
measuring TEER (Millicell-ERS volt-ohm meter, Millipore, Billerica, USA), in triplicate. 
TEER measurements were performed before and after each permeability experiment to 
check the integrity of the cell monolayer. Tightness was expressed as a percentage of the 
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initial TEER. For permeability experiments, complete culture medium of the Caco-2 cell 
was removed from both apical and basolateral compartments and the cells were rinsed 
with DMEM without supplements (transport medium). To 1.5 mL of individual test sam-
ples, 0.399 mL of transport medium was added to achieve the final EPO concentration of 
0.15 mg mL–1. In the apical compartment, 0.5 mL of such tested samples and 1.5 mL trans-
port medium were added into the basolateral compartment. Permeation with the tested 
samples was performed under the same conditions as when the Caco-2 cells were grown. 
Then, 110 µL samples were taken from the basolateral compartment at 30, 60, 120 and 180 
min, which were always replaced by fresh transport medium. As the negative control for 
membrane tightness, the paracellular permeability marker fluorescein was used as previ-
ously described (24). When monolayer integrity during the permeability experiment was 
diminished, the test sample was removed, cells were washed and returned to complete cell 
culture medium, left to regenerate for 24 h, and then TEER was measured again. All the 
permeability experiments were performed as three repeats.
Apparent permeability coefficient and enhancement ratio calculation
The apparent permeability coefficient (Papp) of EPO across the Caco-2 cell monolayer 
was determined and calculated from the measured concentration of EPO in the apical and 
basolateral compartments at determined times according to the following equation de-
rived from Fick’s law for steady state and sink conditions:
 ( )
0
1
= ×
×
app cm s    
dQP /
dt A  c  (2)
where the ratio dQ/dt (mol s–1) was calculated from the linear part of the curve (i.e., increas-
ing mass in the basolateral compartment over time), A (cm2) is the permeation area of the 
membrane, and c0 (mol L–1) is the initial concentration of EPO in the apical compartment. 
EPO concentration was measured on both sides, apical and basolateral, to exclude its pos-
sible metabolic degradation in Caco-2 cells.
As a more immediate measure of these effects of chitosan and CS-TMC NPs on EPO 
permeability in this Caco-2 cell model, enhancement ratios were also calculated. These 
defined Papp of EPO in nanoparticle formulations (Papp EPOformulation) relative to Papp of the 
free EPO (Papp EPOfree), as defined in Eq. (3):
 Enhancement ratio = (Papp EPO formulation / Papp EPO free) (3).
Quantification of erythropoietin
EPO concentrations of collected samples were measured using an in-house sandwich 
ELISA protocol, with commercially available antibodies and reagents. Microtiter plates 
pre-coated with an anti-EPO antibody were incubated with 100 µL of samples at 25 °C for 
1 h, on a horizontal orbital microplate shaker at 500 rpm. After careful removal of all me-
dium, the wells were washed with 400 µL wash buffer and incubated with 100 µL anti-
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human EPO detection antibody, for 1 h, under the same conditions as the testing formula-
tions. The wells were then washed three times with 400 µL wash buffer, and incubated 
with 200 µL horseradish peroxidase conjugated anti-rabbit IgG antibody for 1 h. This was 
followed by another wash. The substrate solution containing 0.35 mg mL–1 3,3’,5,5’-tetra-
methylbenzidine was added, with incubation for 20 to 25 min. The reaction was stopped 
by the addition of 0.1 mL 2 M sulphuric acid solution, and the absorbances at 450 and 600 
nm (for correction) were measured (Synergy HT plate reader, BioTek Instruments, USA). 
EPO concentrations were calculated from the prepared standard curve, which showed 
linearity in a concentration range of 0.015 to 1.0 ng mL–1 (R2 = 0.9999).
Fluorescein was analysed using a microplate reader (FLUOstar Galaxy, BMG Labtech-
nologies GmbH, Germany) at 485 and 530 nm as excitation and emission wavelengths, 
respectively. Fluorescein concentration was calculated from the prepared standard curve, 
which showed linearity in a concentration range of 0.1 ng mL–1 to 0.1 µg mL–1 with the cor-
relation coefficient 0.9998.
Data analysis
Representative data of two or three independent experiments are presented as means 
± standard deviation, with four to six replicates for each experiment. The SPSS 10.0 for 
Windows (SPSS, Chicago, IL) statistical software package was used for data analysis. Sta-
tistical significance for all the tests was accepted at a level of p < 0.05.
RESULTS AND DISCUSSION
The motivation for this study was to design and test a highly sensitive method for 
determination of surface hydrophobicity of protein drugs alone and loaded into NPs. Sur-
face hydrophobicity is an important property of NPs, which influences the fate, transport 
and bioavailability of protein drugs. Previous studies aimed to investigate protein struc-
tural changes, protein adsorption, and conformational changes of protein drugs after their 
loading into NPs (25). Herein, we have determined and characterized the surface hydro-
phobicity of the protein drug EPO alone or incorporated into NPs as an approach to im-
proving protein drug permeation through the intestinal epithelial barrier.
Characteristics of nanoparticles
Polyelectrolyte complexation and ionotropic gelation are the mildest methods of 
nanoparticle preparation, avoiding the use of harsh processing conditions such as organic 
solvents, high energy processing procedures and/or surfactants, which are potentially 
harmful to sensitive biomolecules. In the polyelectrolyte complexation used in the present 
study, the main ionic interactions were between the positive amino groups of the CS or the 
mixture of CS-TMC and negative carboxylic residues of EPO amino-acid to form fragile 
NPs, and later with the phosphate groups of TPP, when stable NPs were made. While this 
crosslinking takes place, the EPO is also loaded into the matrix of the NPs by electrostatic 
and hydrophobic interactions (Fig. 1). Nanoparticle formation is primarily entropy driven 
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due to the intrinsic physicochemical properties of the polycationic polymers used, and the 
anionic EPO, and tripolyphosphate, which occur spontaneously upon this dropwise com-
bination under gentle stirring (10). The mean particle size, polydispersity index and zeta 
potential of the EPO-loaded CS NPs were 300 ± 35 nm, 0.30 ± 0.022 and +30 ± 3 mV, respec-
tively, and for the EPO-loaded CS-TMC NPs were 250 ± 20 nm, 0.31 ± 0.025 and +35 ± 4 mV. 
Colloidal stabilities defined by the surface zeta potentials were close for both of these 
Fig. 2. Representative SEM images of: a) the EPO-loaded chitosan NPs, and b) CS-TMC NPs. Bar size 
100 nm.
a)
 
 
b)
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EPO-loaded NPs (range, +27 to +39 mV), and therefore these nanoparticle dispersions were 
stable. The loading efficiency of EPO into CS/EPO/TPP and CS-TMC/EPO/TPP NPs was 62 
and 33 %, respectively. Lower loading efficiency for CS-TMC/EPO/TPP NPs might be due 
to the steric obstacles of the methyl groups of TMC.
SEM images of dried NPs showed an irregular and spherical to polyhedral shape and 
were seen as clusters of individual NPs, mainly due to the drying under vacuum (Fig. 2). 
However, boundaries between the individual particles were still visible. Estimated sizes 
of the particles obtained from the SEM images were by about 100 to 150 nm smaller than 
those measured using dynamic light scattering. The reason is probably related to the hy-
dration of particles in water for the measurement of the hydrodynamic radius.
Fluorescence intensity of bis-ANS in different media
Fluorescence intensity of the bis-ANS dye is strongly dependent on the polarity of 
the media in which it is dissolved, as shown in Fig. 3. The highest fluorescence intensity 
was observed in acetone, with the lowest dielectric constant of 20.7 As V–1 m–1, followed 
by methanol (32.1 As V–1 m–1) and absolute ethanol (24.5 As V–1 m–1), which showed com-
parable intensities despite the different dielectric constants. In 50 % ethanol, bis-ANS 
showed an even lower intensity compared to absolute ethanol, as expected. In water with 
a dielectric constant of 80.1 As V–1 m–1, bis-ANS showed minimal fluorescence intensity 
(Fig. 3e-g). The data indicate that bis-ANS shows minimal fluorescence in an aqueous 
environment, but becomes highly fluorescent in apolar, organic solvents with low dielec-
tric constants. These data are in agreement with Hawe et al. (18) and Maurel reports (27). 
Fig. 3. Bis-ANS fluorescence intensity in different solvents with various polarities: a) acetone, b) metha-
nol, c) absolute ethanol, d) 50 % (V/V) aqueous ethanol, e) phosphate buffer (pH 7.4), f) 0.25 % (V/V) 
acetic acid, and g) water.
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Overall, this evaluation confirms that the bis-ANS fluorescence intensity is inversely 
correlated with the polarity of the medium, and that it is suitable for the intended inves-
tigation.
Hydrophobicity of the erythropoietin protein molecule in media with different pHs
The impact of medium pH on the hydrophobicity of the EPO protein molecule was 
evaluated in solvents with different pHs, in terms of zeta potentials (Table I). As with EPO, 
many proteins show a pronounced tendency to ionize amino acid residues at a specific pH, 
which results in different polarities of the protein surface (27). To evaluate the surface 
hydrophobicity of EPO alone and loaded in the NPs at different pHs, bis-ANS was used 
because of its different fluorescence intensities upon contact with various hydrophobic 
surfaces. EPO in solvents with different pHs had various negative zeta potentials, and 
therefore showed different tendencies for interactions with bis-ANS. Fluorescence inten-
Table I. Zeta potentials of EPO protein molecules in water media with different pHs. NP medium contains the 
same solvents and buffers with the same pH as used in the prepared NPs
EPO medium pH Zeta potential (mV)
Phosphate buffer 7.4 –10.6 ± 0.2
Water 7.2 –10.4 ± 0.3
NPs medium 5.4 –6.7 ± 0.2
0.25 % (V/V) acetic acid 4.1 –3.6 ± 0.4
Fig. 4. Bis-ANS fluorescence intensity in the presence of EPO in the media with different pHs: a) 0.25 
% (V/V) acetic acid, b) NPs medium, c) water, and d) phosphate buffer (pH 7.4).
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sity reflects the surface hydrophobicity of EPO, which can be partly affected by the medium 
pH due to the exposure of its hydrophobic parts (domains with less charges) on the surface. 
However, detailed information about bis-ANS binding with EPO can be obtained using 
nuclear magnetic resonance and circular dichroism. This trend is consistent with the data 
of Chi et al. (27), who reported that the solution pH can define the type (positive or nega-
tive) and total charge on a protein, thereby affecting the electrostatic interactions and pro-
tein hydrophobicity. The number of charged groups on a protein varies according to the 
pH of the solution.
Fluorescence intensity of bis-ANS alone in the selected water media with different 
pHs was negligible, while the intensity changed significantly (p < 0.05) after EPO addition, 
as shown in Fig. 4. Bis-ANS showed its highest fluorescence intensity in the presence of 
EPO in an acidic environment of 0.25 % (V/V) acetic acid, followed by the NP medium, and 
then even lower at almost neutral pH (i.e., phosphate buffer, water). Explanation of these 
data can be found in the different ionization steps of the EPO molecule at different pHs. 
As the isoelectric point of EPO is 4.4 to 4.8 (23), the effect of ionized groups is the smallest 
close to this pHs, and therefore the hydrophobicity of EPO is the highest (Table I, Fig. 4a). 
The further the pH is from the isoelectric point, the more ionized groups will be found on 
the surface of the globular protein (i.e., greater zeta potential), and the surface will be less 
hydrophobic and more hydrophilic, which is reflected in lower fluorescence intensity (Fig. 
4b-d).
Hydrophobicity of the erythropoietin loaded nanoparticles
The different fluorescence intensities of bis-ANS in the presence of free EPO and EPO-
loaded into NPs and the respective controls are shown in Figs. 5a and 5b. Here, the EPO-
loaded into CS/EPO/TPP NPs showed the highest fluorescence intensity compared to free 
EPO under the same conditions and solvent composition. Fluorescence intensities of the 
empty CS/TPP NPs and chitosan polymer in NPs medium were negligible compared to the 
samples with EPO (Fig. 5a).
Fig. 5b shows fluorescence intensity of the EPO loaded into CS-TMC/EPO/TPP NPs. 
Here, the highest fluorescence intensity was seen for free EPO in the medium for NPs, 
which was thus higher than for the EPO loaded into CS-TMC/EPO/TPP NPs (Fig. 5b). 
Comparison of fluorescence intensities between EPO loaded into both types of NPs 
indicated higher hydrophobicity for CS/EPO/TPP than for CS-TMC/EPO/TPP NPs. This 
was most likely due to the charges on NP surfaces as a consequence of the different EPO 
complexation to each of these polymers. Hydrophobicity probably reflected fewer interac-
tions between TMC and EPO compared to CS.
The CS and CS-TMC mixture, recorded solely in NP medium, and also after crosslink-
ing with TPP to form empty NPs, resulted in low values of bis-ANS fluorescence, indicat-
ing a highly charged NP surface. Our experimental data fit the Cooper et al. (25) report, 
where they concluded that interactions of proteins with polyelectrolyte carriers reduce the 
dielectric environment of the protein, which can result in increased fluorescence intensity, 
and thus reflects higher surface hydrophobicity after its complexation into NPs. However, 
the fluorescence intensity of these CS-TMC/EPO/TPP NPs was slightly higher than the 
empty CS-TMC/TPP NPs (i.e., 11,406 compared to 7,607). The lower hydrophobicity of CS-
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TMC/EPO/TPP NPs might be a consequence of the remaining charges at CS-TMC poly-
mers due to the low EPO loading ability.
In addition, this study opened more options to increase the protein drug loading in 
polyelectrolyte nanoparticles if the type and structure of the polymer, surface charge den-
sity and pH value of the medium are selected properly. Consequently, local structural 
features, such as the arrangement of polymer segments in their ‘‘bound state’’ on a 0.5–10 
nm scale, need to fit the binding domain of the protein drug. Thus, higher loading ability 
promotes electrostatic interactions and shifts the protein molecule polarity.
Based on fluorescence intensities, it can be concluded that the EPO loaded into CS/
EPO/TPP NPs shows the most hydrophobic character, followed by free EPO in medium 
and then the EPO loaded into CS-TMC/EPO/TPP NPs. In further experiments, the impact 
of hydrophobicity on the permeability of the model drug EPO loaded into both types of 
NPs was evaluated in vitro.
Monitoring Caco-2 cell monolayer integrity by transepithelial electrical resistance
One of the mechanisms of NPs to facilitate the permeation of protein drugs is to com-
promise an epithelial monolayer. Therefore, the monolayer tightness was examined using 
the transport of the paracellular permeability marker, fluorescein, at the same concentra-
tion as EPO (0.15 mg mL–1) to confirm the suitability of this Caco-2 model for testing per-
meability. The Papp for fluorescein was consistent throughout the transport experiments, 
with a mean of 3.1 ± 1.5 × 10–8 cm s–1 and was lower than those from other laboratories (22). 
In addition, the monitoring of the Caco-2 cell monolayer was evaluated by measuring 
TEER, and the return to the initial TEER after permeation. In general, TEER is used to 
define the tightness of the junctions between cells, and thus the disturbance of the junc-
tions is also reflected in changes to TEER. TEER was monitored at the start of each experi-
ment, during the 3-h experimental incubations, and then 24 h after them. In all cases where 
the TEER was > 2 kΩ cm2 at the start, this was accepted as the appropriate monolayer in-
tegrity for permeability experiments. In general, TEER values ranging from 0.15 to 1 kΩ 
cm2 have been reported (7, 21–23). Higher TEER measurements along with lower Papp of 
fluorescein indicate that the Caco-2 cell monolayers used in our experiments are tighter 
than those reported elsewhere (22).
Following the 3-h incubations of Caco-2 monolayers with apical application of EPO 
loaded into CS/EPO/TPP or CS-TMC/EPO/TPP NPs, significant TEER decreases were ob-
served. While the free EPO in NP medium did not affect the TEER, after its complexation 
into CS/EPO/TPP NPs it reduced it by 80 %, and into CS-TMC/EPO/TPP NPs by 77 % (Table 
II). The recovery period for TEER after the removal of free EPO in NP medium and EPO 
loaded into CS and CS-TMC NPs (i.e., 24 h) saw TEER restoration to 70 % of the initial 
value. These data did not match those of Sadeghi et al. (28), who reported that the decrease 
in TEER for CS NPs was only about 15 % after 5 h of incubation with Caco-2 cells. This 
might be due to the lower zeta potential of NPs (+ 15.9 ± 0.5 mV) and smaller particle size 
(around 200 nm) prepared by Sadeghi et al. (28). It is known that the surface charge den-
sity of NPs and their size also affect their ability to interact with the components of tight 
junctions and compromise them to allow particle absorption.
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Permeability of erythropoietin protein molecules and nanoparticles through Caco-2 cells
In previous sections, hydrophobicity of the investigated samples and the membrane 
integrity were presented, while here the impact of the hydrophobic nature of these EPO 
samples on their ability to cross the Caco-2 cell monolayers was investigated. The data 
from these permeation experiments are given as the calculated apparent permeability 
coefficient, Papp, and enhancement ratio, as shown in Table II.
Fig. 5. Bis-ANS fluorescence intensity for EPO free and loaded into the CS and CS-TMC nanoparticle 
systems: a) CS/EPO/TPP NPs (a), free EPO in NPs medium (b), empty CS/TPP NPs (c), chitosan poly-
mer in NP medium (d), and NP medium alone (e); b) CS-TMC/EPO/TPP NPs (a), free EPO in NP me-
dium (b), empty CS-TMC/TPP NPs (c), CS-TMC polymer mixture in NP medium (d), and NP medium 
alone (e). All samples were recorded in the same dispersion media (NP medium), having a pH of 5.4.
a)
b)
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The mean Papp defined higher permeability across the Caco-2 cell monolayers for EPO 
loaded into CS NPs, followed by EPO loaded into CS-TMC NPs, and then free EPO. En-
hancement ratios as their Papp relative to that of free EPO in NPs medium (Table II) were 
636 for CS/EPO/TPP NPs but only 42 for CS-TMC/EPO/TPP NPs. Thus, these CS NPs were 
much more effective in promoting the permeation of EPO across the Caco-2 cell mono-
layer than the CS-TMC NPs. While for the EPO-loaded CS NPs this parallels their higher 
hydrophobicity, the EPO-loaded CS-TMC NPs had lower hydrophobicity compared to that 
of free EPO in NP medium. This indicates the reverse, since despite this lower hydropho-
bicity, the permeability of EPO-loaded into CS -TMC/EPO/TPP was higher than for free 
EPO in NP medium. To conclude, encapsulations of protein drugs into polyelectrolyte NPs 
increased protein hydrophobicity and reduced their size, thus allowing them to pass the 
epithelial barrier.
Although Li et al. (13) and Mohammed et al. (29) reported that hydrophobic NPs can 
undergo inclusion into the membrane, whereas semihydrophilic NPs will adsorb onto the 
membrane, this is not the only mechanism to improve protein absorption. NP parameters 
that can affect cellular uptake, protein binding and translocation of the NPs through the 
cell are also size, chemical composition, shape, surface charge density and their aggrega-
tion (15). However, at this level, definition of the detailed mechanisms behind the perme-
abilities of these NPs with these mixtures of polymers will require further, more detailed 
analyses. Furthermore, although most studies have reported CS enhancement of intesti-
nal paracellular permeation, some studies have also shown that it can directly affect both 
paracellular and transcellular permeation. Thus, they defined CS and TMC (either in 
solution or as NPs) as permeation enhancers to improve the permeability through the 
intestinal epithelium of macromolecule drugs (6, 28, 29). They also indicated that the 
highly positively charged TMC provides increased permeability of macromolecular 
drugs across the intestinal cells, compared to CS (29). Data from the present study show 
that the permeability of CS-TMC/EPO/TPP NPs was lower than for CS/EPO/TPP NPs al-
though the EPO-loaded into CS-TMC NPs had higher positive net charge, which might 
better interact with the negatively charged interior of tight junctions and thus open the 
paracellular route.
Table II. EPO formulations and their effects on TEER of the Caco-2 cell model after 3-h treatments, and after 
24-h recovery, and the apparent permeability coefficient
Sample
Concentrations 
(mg mL–1)
Transepithelial electrical 
resistance (% initial) Papp EPO
(cm s–1)
Enhancement 
ratio (Papp 
sample/ Papp 
EPO)
Following 3 h 
treatment
Following 24 h 
recovery
EPO in NPs medium 0.15 100 100 4.09 ± 0.2E-10 /
CS/EPO/TPP 1.0/0.15/0.225 20 70 2.60 ± 0.3E-07 636
CS-TMC/EPO/TPP 1.0/0.15/0.225 23 70 1.71 ± 0.1E-08 42
Papp – calculated apparent permeability coefficient
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Furthermore, to investigate the influence of NPs prepared in this study on the perme-
ability through the mucus and intestinal barriers, additional methods (e.g., confocal mi-
croscopy) and in vitro cell model (e.g., Caco-2/MT 29 co-cultured cells) should be used. 
There Caco-2 cells simulate the intestinal epithelium and its tightness, the MT29 cells secret 
mucus and simulate an intestinal mucus layer with lower TEER. So far, we have proved 
the impact of hydrophobic effects of these polyelectrolyte NPs on the permeability of EPO 
protein drugs through the intestinal barrier, but the issues of mucus permeation remain 
open. The difference in surface charge density of investigated NPs would probably also 
affect the permeation through the mucus, as also reported by de Sousa (30).
CONCLUSIONS
The present study is focused on investigating the surface hydrophobicity of free EPO, 
as a model protein drug, and loaded into NPs, to determine any correlations with perme-
ation through an intestine epithelium model. Surface hydrophobicity was determined us-
ing the extrinsic fluorescent dye bis-ANS, which showed specific polarity-sensitive bind-
ing. These data show that under a variety of polarities and pHs of the medium, EPO 
undergoes surface changes that reflect different surface hydrophobicities. The highest 
surface hydrophobicity of EPO was observed at around pH 5, where it had the lowest ion-
ization. A direct correlation between fluorescence intensity of bis-ANS and polarity con-
firmed an experimental metric for prediction of relative surface hydrophobicity. CS/EPO/
TPP NPs showed higher hydrophobicity than CS-TMC/EPO/TPP NPs, and when evaluated 
in vitro with Caco-2 cell monolyers, also higher Papp, while free EPO in NPs medium 
showed the lowest Papp. The study confirms that surface polarity of nanosized particles 
represents an important parameter in protein permeability in the intestine. We can thus 
conclude that these data suggest that the complexation of hydrophilic protein drug mole-
cules with polyelectrolytes may form more hydrophobic NPs enhancing protein drug per-
meability through the epithelial layer. Finally, this concept can be used with practically 
any type of protein drugs where polyelectrolyte complexation principles are taken into 
account. Combination of bis-ANS and the permeability study also provide a valuable ap-
proach that will help in the development phase of new therapeutic protein drugs and their 
delivery systems, since this approach requires relatively little sample consumption and 
less time in comparison with other biophysical methods. 
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